Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 6,816 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 6,816 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $93.13, for a total transaction of $634,774.08. Following the completion of the sale, the chief executive officer now directly owns 227,710 shares of the company’s stock, valued at $21,206,632.30. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The shares were sold at an average price of $90.42, for a total transaction of $240,698.04.
• On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The shares were sold at an average price of $88.96, for a total transaction of $7,403,518.08.
• On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The shares were sold at an average price of $88.36, for a total transaction of $824,045.36.
• On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The shares were sold at an average price of $65.09, for a total transaction of $964,178.17.
• On Monday, January 22nd, Steven Leonard Chapman sold 1,958 shares of Natera stock. The shares were sold at an average price of $68.16, for a total transaction of $133,457.28.

Natera Stock Performance

NASDAQ NTRA opened at $85.28 on Friday. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $98.82. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The stock has a market capitalization of $10.30 billion, a PE ratio of -22.50 and a beta of 1.37. The company’s 50 day simple moving average is $86.05 and its two-hundred day simple moving average is $65.85.

Natera (NASDAQ:NTRA) last posted its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The business had revenue of $311.11 million for the quarter, compared to analysts’ expectations of $300.38 million. Analysts predict that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NTRA. Stephens reissued an “overweight” rating and set a $78.00 target price on shares of Natera in a research report on Tuesday, January 30th. Craig Hallum started coverage on shares of Natera in a research report on Monday, April 8th. They set a “buy” rating and a $117.00 target price for the company. BTIG Research upped their price target on shares of Natera from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Friday, December 29th. The Goldman Sachs Group upped their price target on shares of Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, April 15th. Finally, Canaccord Genuity Group upped their price target on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. One research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and an average price target of $86.40.

Institutional Trading of Natera

Several institutional investors and hedge funds have recently bought and sold shares of NTRA. Allspring Global Investments Holdings LLC increased its holdings in shares of Natera by 28.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock worth $45,111,000 after buying an additional 159,993 shares during the last quarter. Cerity Partners LLC increased its holdings in shares of Natera by 1,043.3% in the 4th quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock worth $5,664,000 after buying an additional 82,514 shares during the last quarter. WCM Investment Management LLC increased its holdings in shares of Natera by 101.2% in the 4th quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock worth $9,058,000 after buying an additional 73,419 shares during the last quarter. Aigen Investment Management LP bought a new position in shares of Natera in the 3rd quarter worth $223,000. Finally, Sei Investments Co. increased its holdings in shares of Natera by 33.4% in the 3rd quarter. Sei Investments Co. now owns 374,004 shares of the medical research company’s stock worth $16,550,000 after buying an additional 93,556 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.